

Author Index to Volume 7

- Aapro MS. *See* Piamsomboon S, 800
- Abderrabi M *et al.* Comparative *in vitro* evaluation of dithiane analogs of tiapamil, Ro 11-2933, Ro 44-5911 and Ro 44-5912 as multidrug resistance modulators, 430
- Abigergeres D *et al.* Phase I and pharmacology study of intopicline (RP 60475; NSC 645008), a novel topoisomerase I and II inhibitor, in cancer patients, 166
- Abraham T. *See* Nusbaum NJ, 109
- Abu-Ghazaleh A. *See* Dwivedi C, 792
- Aikou T. *See* Nakamura K, 235
- Akiyama N. *See* Kizu R, 248
- Al-Katib A. *See* Maki A, 344
- Al-Obaid AM *et al.* 5-Substituted-2-thiohydantoin analogs as a novel class of antitumor agents, 873
- Alberts DS. *See* Malviya VK, 527; *also* Valcic S, 461
- Albuisson E. *See* Cayre A, 833
- Alessio E. *See* Bergamo A, 697
- Algour N. *See* Ayesh S, 678
- Alvarez E. *See* Saunders PP, 93
- Anderson H. *See* Martin C, 351
- Andreotti PE. *See* Cree IA, 630
- Arimilli S. *See* Saunders PP, 93
- Armand J-P. *See* Abigergeres D, 166
- Asakura T. *See* Takahashi N, 687
- Avilés A *et al.* Results of randomized trial of granulocyte colony-stimulating factor in patients with infection and severe granulocytopenia, 392
- Ayesh S *et al.* Reversal of P-glycoprotein is greatly reduced by the presence of plasma but can be monitored by an *ex vivo* clinical assay, 678
- Baba M. *See* Nakamura K, 235
- Bajardi G. *See* Gebbia V, 386
- Barrows LR. *See* Kokoshka JM, 758
- Bayssas M. *See* Abigergeres D, 166
- Bear HD *et al.* Bryostatin 1 activates splenic lymphocytes and induces sustained depletion of splenocyte protein kinase C activity *in vivo* after a single intravenous administration, 299
- Beauséjour C. *See* Momparler RL, 266
- Beijnen JH. *See* Sparreboom A, 78
- Bender E. *See* Werner A, 307
- Bergamo A *et al.* Treatment of residual metastases with Na[*trans*-RuCl₄(DMSO)]m and ruthenium uptake by tumor cells, 697
- Bergström P. *See* Crnalic S, 489
- Bertolissi A. *See* Rizzi V, 846
- Bertram J *et al.* Increase of P-glycoprotein mediated drug resistance by hsp 90-β, 838
- Bianca J. *See* Piamsomboon S, 800
- Bissery MC *et al.* Experimental antitumor activity and pharmacokinetics of the camptothecin analog irinotecan (CPT-11) in mice, 437; *also* Abigergeres D, 166
- Blackledge G *et al.* Bicalutamide: a new antiandrogen for use in combination with castration for patients with advanced prostate cancer, 27
- Bokemeyer C. *See* Dunn TA, 795
- Borg-Karlson A-K. *See* Karlson J, 422
- Borsellino N. *See* D'Alessandro N, 281
- Borsi JD *et al.* Administration of Ethylol (amifostine) to a child with medulloblastoma to ameliorate hematological toxicity of high dose carboplatin, 121
- Borut-Mintz S. *See* Sela J, 579
- Bosanquet N. *See* Johnson N, 130
- Bošnjak SM. *See* Neškovic-Konstantinovic, 543
- Boyer R. *See* Saarinen A, 890
- Bready B. *See* Pazdur R, 728
- Broström L-A
- Brown DM. *See* Singh SS, 507
- Bruckner HW. *See* Cree IA, 630
- Bruno R. *See* Abigergeres D, 166
- Buquet-Fagot C. *See* Raymond E, 752
- Buss JL. *See* Hasinoff BB, 558
- Calastretti A. *See* Tondelli L, 189
- Cannata G. *See* Gebbia V, 386; *also* Gebbia V, 734
- Capozzi I. *See* Bergamo A, 697
- Capson TL. *See* Kokoshka JM, 758
- Carbonell E *et al.* Cytogenetic analysis in peripheral lymphocytes of cancer patients treated with cytostatic drugs: results from an EC Collaborative Study, 514
- Carr M. *See* Bear HD, 299
- Carr S. *See* Bear HD, 299
- Cartei F *et al.* A phase II study of oral fluorouracil for gastrointestinal cancer, 48
- Cartei G. *See* Cartei F, 48; *also* Rizzi V, 846
- Cascinu S *et al.* Different doses of granulocyte colony stimulating factor to support a weekly chemotherapeutic regimen in advanced gastric cancer: a randomized study, 43; *also* A phase I trial of 5-fluorouracil, leucovorin and interferon-α2b administered by 24 h infusion in metastatic colorectal carcinoma, 520
- Casertini C. *See* Supino R, 604
- Casper J. *See* Dunn TA, 795
- Catalano G. *See* Cascinu S, 43; *also* Cascinu S, 520
- Catimel G. *See* Abigergeres D, 166
- Cavallin-Stahl E. *See* Johnsson A, 70
- Cayre A *et al.* *In vitro* detection of the MDR phenotype in rat myocardium: use of PCR, [³H]daunomycin and MDR reversing agents, 833
- Cemazar M. *See* Serša G, 785
- Chabot GG. *See* Abigergeres D, 166; *also* Bissery MC, 437
- Chaitchik S. *See* Ron IG, 649
- Chang D. *See* Jacquet P, 596
- Cherif A. *See* Inoue T, 858
- Chollet P. *See* Martineau-Pivoteau N, 703
- Chowers I *et al.* Vinblastine toxicity to the ocular surface, 805
- Cimoli G. *See* Debernardis D, 531
- Cinatl J. *See* Cinatl Jr, J, 766
- Cinatl Jr, J *et al.* Antitumor activity of sodium valproate in cultures of human neuroblastoma cells, 766
- Cioschi B. *See* Rizzi V, 846
- Clavel M. *See* Abigergeres D, 166
- Clements MK *et al.* Camptothecin exhibits selective cytotoxicity towards human breast carcinoma as compared to normal bovine endothelial cells *in vitro*, 851
- Clow KA. *See* Minchinton AI, 339
- Cocchietto M. *See* Bergamo A, 697
- Colofiore JR. *See* Martin DS, 655; *also* Stolfi RL, 100
- Colucci G. *See* Gebbia V, 386
- Conrad ME. *See* Malviya VK, 527
- Copreni E. *See* Tondelli L, 189
- Corthouts B. *See* Dirix IY, 175
- Cournoyer D. *See* Momparler RL, 266
- Courtois A. *See* Fardel O, 671
- Cree IA *et al.* Correlation of the

- clinical response to chemotherapy in breast cancer with *ex vivo* chemosensitivity, 630
- Crnalic S *et al.* Antagonistic effect of amphotericin B on carboplatin anti-tumor activity in human osteosarcoma xenografts, 489
- Crouzet M. *See* Hu Y-P, 738
- Csaki C. *See* Borsi JD, 121
- Cummings J *et al.* Molecular modeling of the interaction of anthracenyl-amino acid topoisomerase inhibitors with the DNA sequence d(CGTACG), 636
- Cussac-Buchdahl C. *See* Martineau-Pivoteau N, 703
- Cyong J-C. *See* Kobayashi T, 195
- D'Alessandro N & Borsellino N. *In vitro* effects of tumor necrosis factor- α or flavone acetic acid in combination with doxorubicin on multidrug-resistant B16 melanoma, 281
- Dahrouge S. *See* Goss GD, 363
- Daoud SS. *See* Clements MK, 851
- Darcel E. *See* Massart C, 321
- Darling JL. *See* Haselsberger K, 331
- Davey MW. *See* Mote PA, 181
- Davey RA. *See* Mote PA, 181
- De Bruijn EA. *See* Egelmeers A, 586
- De Schepper B. *See* Dirix IY, 175
- Debernardis D *et al.* Interactions between taxol and camptothecin, 531
- DeCaro L. *See* Piamsomboon S, 800
- Degen D. *See* Izquierdo MA, 275
- Del Ferro E. *See* Cascinu S, 43; *also* Cascinu S, 520
- del Roble Velazco M *et al.* Genotoxic effects of *Karwinskia humboldtiana* toxin T-5114 in peripheral blood lymphocytes, 710
- Delclos L. *See* Piamsomboon S, 800
- Dellemijn PJI & Vecht CJ. Towards better pain treatment in cancer, 3
- DeMoor C. *See* Weiss GR, 402
- Demopoulos NA. *See* Carbonell E, 514
- Denais A. *See* Massart C, 321
- Dewar JA. *See* Cree IA, 630
- Diaz-Canton E. *See* Pazdur R, 728
- Diaz-Maqueo JC. *See* Aviles A, 392
- Didier A *et al.* Detection of P-glycoprotein expression by tumoral cells with NBDL-C8A, a fluorescent derivative of cyclosporin A, 257; *also* Didier A & Looer E. The abamectin derivative ivermectin is a potent P-glycoprotein inhibitor, 745
- Dirix IY *et al.* Long-term results of continuous treatment with recombinant interferon- α in patients with metastatic carcinoid tumors—an antiangiogenic effect, 175; *also* Egelmeers A, 586
- Djelloul S. *See* Raymond E, 752
- Doerr HW. *See* Cinatl Jr. J, 766
- Doignon E. *See* Hu Y-P, 738
- Doll K. *See* Strumberg D, 415
- Donchower RC. *See* O'Reilly S, 410
- Drenou B. *See* Fardel O, 671
- Dunn TA *et al.* Amifostine does not alter the antitumor activity of cisplatin in a pre-clinical model of testicular cancer, 795
- Durga Govindaraju K. *See* Maki A, 344
- Dwivedi C *et al.* Effects of diallyl sulfide and diallyl disulfide on cisplatin-induced changes in glutathione and glutathione-S-transferase activity, 792
- Eckardt JR. *See* Weiss GR, 402
- Edwards CL. *See* Kudelka AP, 398; *also* Kudelka AP, 885; *also* Piamsomboon S, 800; *also* Termrungruangert W, 503
- Egelmeers A *et al.* The influence of hypoxia on the cytotoxicity of concomitant KW-2149 and ionizing irradiation in Chinese hamster fibroblasts, 586
- El-Subbagh HI. *See* Al-Obaid AM, 873
- Eliopoulos N. *See* Mompalmer RL, 266
- Elmazar MMA. *See* Al-Obaid AM, 873
- Ende K. *See* Kudelka AP, 398
- Eriguchi M. *See* Kizu R, 248
- Evans SL. *See* Johnson DE, 288
- Fardel O *et al.* Inhibition of P-glycoprotein activity in human leukemic cells by mifepristone, 671
- Fauchet R. *See* Fardel O, 671
- Fco M. *See* Gebbia V, 386
- Ferencz T. *See* Borsi JD, 121
- Fierens H. *See* Dirix IY, 175
- Finat-Duclos E. *See* Cayre A, 833
- Fishman A. *See* Kudelka AP, 398
- Freedman RS. *See* Kudelka AP, 398; *also* Piamsomboon S, 800
- Fridborg H *et al.* Correlation between sensitivity *in vitro* of patient chronic lymphocytic leukemia cells and clinical systemic exposure at the maximum tolerated dose for cell cycle phase-specific (type 2) anti-cancer drugs, 105
- Frucht-Pery J. *See* Chowers I, 805
- Fryer KH. *See* Minchinton AI, 339
- Fukumoto T. *See* Nakamura K, 235
- Fukushima M. *See* Shirasaka T, 548
- Garbesi A. *See* Tondelli L, 189
- Garcia EL. *See* Aviles A, 392
- Gebbia N. *See* Gebbia V, 386; *also* Gebbia V, 734
- Gebbia V *et al.* Subcutaneous low-dose interleukin-2 and intravenous 5-fluorouracil plus high-dose levofol-
- nic acid as salvage treatment for metastatic colorectal carcinoma, 386; *also* Treatment of cisplatin-related nausea and vomiting with a combination of ondansetron and metoclopramide: a pilot study, 734
- Gerl A & Wilmanns W. Antitumor activity of paclitaxel after failure of high-dose chemotherapy in a patient with late relapse of a non-seminomatous germ cell tumor, 716
- Geromichalos GD *et al.* *In vitro* synergistic effects of some novel Cu(II) complexes in combination with epirubicin and mitomycin C against HeLa-S3 cervical cancer cell line, 469
- Gespach C. *See* Raymond E, 752
- Gibassier J. *See* Massart C, 321
- Giraldi T. *See* Cartei E, 48
- Goldberg DA. *See* Malviya VK, 527
- Gong L. *See* Tondelli L, 189
- Gonsebatt ME. *See* del Roble Velazco M, 710
- Goss GD *et al.* Recent advances in the treatment of non-small cell lung cancer, 363
- Gourdiere B. *See* Mouchard-Delmas C, 213
- Grant S. *See* Bear HD, 299
- Griffon-Etienne G *et al.* Association of docetaxel/paclitaxel with irradiation in ovarian carcinoma cell lines in bidimensional (sulforhodamine B assay) and tridimensional (spheroids) cultures, 660
- Grochow LB. *See* O'Reilly S, 410
- Grünwald V. *See* Dunn TA, 795
- Guenther J. *See* Dwivedi C, 792
- Guillen JM. *See* Valcic S, 461
- Gulliya KS. *See* Sharma R, 293
- Guzmán R. *See* Aviles A, 392
- Hadfield JA. *See* Cummings J, 636
- Hadjikostas CC. *See* Geromichalos GD, 469
- Hagiwara A *et al.* New formulation of 5-fluorouracil in microspheres reduces toxicity in mice, 780; *also* Tsujimoto H, 240
- Hall AK. Liarozole amplifies retinoid-induced apoptosis in human prostate cancer cells, 312
- Hall III. *See* Huang Y, 613
- Halme M. *See* Saarinen A, 890
- Hamad GG. *See* Bear HD, 299
- Hamatake M. *See* Ishida R, 591
- Haneda T. *See* Une Y, 881
- Hantel A. *See* Malviya VK, 527
- Harstrick A. *See* Strumberg D, 415
- Haselsberger K *et al.* Assay of anti-cancer drugs in tissue culture: comparison of a tetrazolium-based assay and a protein binding dye assay in

- short-term cultures derived from human malignant glioma, 331
- Hasinoff BB *et al.* The effect of dexrazoxane (ICRF-187) on doxorubicin and daunorubicin-mediated growth inhibition of Chinese hamster ovary cells, 558
- Havsteen H & Kjaer M. Antiemetic treatment with two different doses of methylprednisolone in breast cancer patients: a double-blind randomized cross-over study with evaluation of efficacy parameters, 535
- Hayes MMM. *See* Minchinton AI, 339
- Hehn BM. *See* Shah RM, 204
- Henrich D. *See* Cinatl Jr. J, 766
- Henriksson R. *See* Crnalic S, 489
- Hernáiz Driever P. *See* Cinatl Jr. J, 766
- Hiddemann W. *See* Bertram J, 838
- Ho DH. *See* Pazdur R, 728
- Hoffman B. *See* Strumberg D, 415
- Holden JA. *See* Kokoshka JM, 758
- Horn Y. *See* Sela J, 579
- Hsueh S. *See* Liu C-T, 228
- Hu Y-P *et al.* Effects of modulators of multidrug resistance on the expression of the MDRI gene in human KB cells in culture, 738
- Huang Y & Hall IH. Antineoplastic activities of 2,3,4-chloro-substituted β -alkylaminopropiophenone derivatives in CF₁ mice and in murine and human tumor cells, 613
- Hunter EM. *See* Cree IA, 630
- Hunter NR. *See* Li C, 642; *also* Inoue T, 858
- Iacopino E. *See* Sica G, 150
- Iijima K. *See* Kobayashi T, 195
- Ikada Y. *See* Hagiwara A, 780
- Imanishi T. *See* Hagiwara A, 780; *also* Tsujimoto H, 240
- Imperato A. *See* Cartei F, 48
- Inbar MJ. *See* Ron IG, 649
- Inoue T *et al.* Evaluation of [¹⁵¹I] iodoerythronitroimidazole as a predictor for the radiosensitizing effect, 858; *also* Kuang L, 220; *also* Li C, 642
- Interlandi G. *See* Cartei F, 48
- Ireland CM. *See* Kokoshka JM, 758
- Ishida R *et al.* Antitumor activity of 2-amino-4, 4a-dihydro-4a,7-dimethyl-3H-phenoxazine-3-one, a novel phenoxazine derivative produced by the reaction of 2-amino-5-methylphenol with bovine hemolysate, 591
- Ito H. *See* Ishida R, 591
- Itoh Y. *See* Watanabe T, 825
- Iwai M. *See* Ishida R, 591
- Izadnegahdar MF. *See* Shah RM, 204
- Izquierdo MA *et al.* Antiproliferative effects of interleukin-12 treatment on human tumor colony-forming units taken directly from patients, 275
- Jacquet P *et al.* Effects of intra-abdominal pressure on pharmacokinetics and tissue distribution of doxorubicin after intraperitoneal administration, 596
- James EA. *See* Cree IA, 630
- Jekunen A. *See* Saarinen A, 890
- Johnson DE *et al.* Phenylacetic acid halides inhibit estrogen receptor (ER)-positive MCF-7 cells, but not ER-negative human breast cancer cells or normal breast epithelial cells, 288
- Johnson N & Bosanquet N. Reply to Thwaites *et al.*, 130
- Johnsson A & Cavallin-Ståhl E. A topographic study on the distribution of cisplatin in xenografted tumors on nude mice, 70; *also* Johnsson A *et al.* Metoclopramide as a modulator of cisplatin: effects on pharmacokinetics and cisplatin-DNA adducts in tumor and normal tissue, 483
- Kabickova H. *See* Cinatl Jr. J, 766
- Kaisary A *et al.* Absence of hepatic enzyme induction in prostrate cancer patients receiving 'Casodex' (bicalutamide), 54
- Kamiyama T. *See* Une Y, 881
- Kaplan A. *See* Kudelka AP, 398
- Kariyazono H. *See* Nakamura K, 235
- Karlson J *et al.* Inhibition of tumor cell growth by monoterpenes *in vitro*: evidence of a Ras-independent mechanism of action, 422
- Kato T. *See* Shirasaka T, 548
- Katoh A. *See* Werner A, 307
- Katsoulos GA. *See* Geromichalos GD, 469
- Kaur G & Sausville EA. Altered physical state of p21^{herabl} in tyrphostin AG957-treated K562 cells, 815
- Kavanagh JJ. *See* Kudelka AP, 398; *also* Kudelka AP, 885; *also* Piamsomboon S, 800; *also* Termrungruanglert W, 503
- Kawai H. *See* Ishida R, 591
- Kemeny N. Colorectal cancer—an undertreated disease, 623
- Khodair AI. *See* Al-Obaid AM, 873
- Kidani Y. *See* Kizu R, 248
- Kieback DG. *See* Kudelka AP, 398
- Kim EE. *See* Inoue T, 858; *also* Li C, 642
- Kizu R *et al.* An orally active anti tumor cyclohexanediamine-Pt(IV) complex: *trans*, *cis*, *cis*-bis(*n*-valera-
- to) (oxalato) (1*R*,2*R*-cyclohexanediamine)-Pt(IV), 248
- Kjaer M. Combining 5-fluorouracil with interferon- α in the treatment of advanced colorectal cancer: optimism followed by disappointment, 35; *also* Havsteen H, 535
- Kjellén E. *See* Johnsson A, 483
- Klarskov P. *See* Kaisary A, 54
- Klink-Alakl M. *See* Abigergeres D, 166
- Kneba M. *See* Bertram J, 838
- Kobayashi T *et al.* Effects of lycopene, a carotenoid, on intrathymic T cell differentiation and peripheral CD4/CD8 ratio in a high mammary tumor strain of SHN retired mice, 195
- Kokoshka JM *et al.* Differences in the topoisomerase I cleavage complexes formed by camptothecin and warkayin, a DNA-intercalating marine natural product, 758
- Kolvenbag G. *See* Blackledge G, 27
- Kornhuber B. *See* Cinatl Jr. J, 766
- Kortsaris AH. *See* Geromichalos GD, 469
- Kostuchenko PJ. *See* Bear HD, 299
- Kotnik A. *See* Serša G, 785
- Kotnik V. *See* Serša G, 785
- Krohn K. *See* Saunders PP, 93
- Krutzsch M. *See* Valcic S, 461
- Kuang L *et al.* Percutaneous intratumoral injection of cisplatin microspheres in tumor-bearing rats to diminish acute nephrotoxicity, 220
- Kurbacher CM. *See* Cree IA, 630
- Kudelka AP *et al.* Preliminary report of the activity of docetaxel in advanced or recurrent squamous cell cancer of the cervix, 398; *also* Remission of advanced uterine leiomyosarcoma with pulmonary metastases with carboplatin and paclitaxel, 885; *also* Piamsomboon S, 800; *also* Termrungruanglert W, 503
- Kudo H. *See* Sakamoto S, 199
- Kumanohoso T. *See* Nakamura K, 235
- Kwiatkowski E. *See* Martineau-Pivoteau N, 703
- Kyriakidis DA. *See* Geromichalos GD, 469
- Laliberté J. *See* Mompalmer RL, 266
- Lamy T. *See* Fardel O, 671
- Lan L-B. *See* Lyubimov E, 60
- Larsson R. *See* Fridborg H, 105
- Lassere Y. *See* Pazdur R, 728
- Lavelle F. *See* Bissery MC, 437
- Le Prise P-Y. *See* Fardel O, 671
- Lecureur V. *See* Fardel O, 671
- Levi F. *See* Martineau-Pivoteau N, 703
- Levy T. *See* Kudelka AP, 398
- Li C *et al.* Synthesis and evaluation of water-soluble polyethylene glycol-

- paclitaxel conjugate as a paclitaxel prodrug, 642
- Liau C-T *et al.* Intra-abdominal desmoplastic small cell tumors: report of two cases, 228
- Lifshitz S. *See* Termrungruanglert W, 503
- Ligi M. *See* Cascinu S, 520
- Lina Tirrito M. *See* Gebbia V, 386
- Linder S. *See* Karlson J, 422
- Ling Y. *See* Hasinoff BB, 558
- Lipsky KA. *See* Bear HD, 299
- Liu PY. *See* Malviya VK, 527
- Liu WC. *See* Kuang L, 220
- Lochrin CA. *See* Goss GD, 363
- Löfvenberg R. *See* Crnalic S, 489
- Lokicc F *et al.* Phenobarbital administration does not affect high-dose ifosfamide pharmacokinetics in humans, 893
- Loor E. *See* Didier A, 257; *also* Didier, 745; *also* Tiberghien F, 568
- Lotan A. *See* Ron IG, 649
- Lucas C. *See* Massart C, 321
- Lugassy G & Shapira A. A prospective cohort study of the effect of vincristine on audition, 525
- Lund B. *See* Martin C, 351
- Lyczek J. *See* Egelmeers A, 586
- Iyubimov E *et al.* Effect of modulators of the multidrug resistance pump on the distribution of vinblastine in tissues of the mouse, 60; *also* Ayesh S, 678
- Mackenzie H. *See* Retsas S, 161
- Madelmont J-C. *See* Martineau-Pivoteau N, 703
- Macemura M. *See* Sakamoto S, 199
- Mahaffey W. *See* Werner A, 307
- Majello E. *See* Gebbia V, 386
- Maki A *et al.* Effect of dolastatin 10 on human non-Hodgkin's lymphoma cell lines, 344
- Malviya VK *et al.* A phase II trial of piroxantrone in endometrial cancer: Southwest Oncology Group Study 8918, 527
- Manfroi S. *See* Tosi P, 774
- Mante RP. *See* Kudelka AP, 398; *also* Termrungruanglert W, 503
- Marchal C. *See* Griffon-Etienne G, 660
- Marchal S. *See* Abderrabi M, 430
- Marcos R. *See* Carbonell E, 514
- Marrangoni A. *See* Werner A, 307
- Marsilio P. *See* Rizzi V, 846
- Martin C *et al.* Gemcitabine: once-weekly schedule active and better tolerated than twice-weekly schedule, 351
- Martin DS *et al.* Marked enhancement *in vivo* of paclitaxel's (taxol's) tumor-regressing activity by ATP-depleting modulation, 655; *also* Stolli RL, 100
- Martineau-Pivoteau N *et al.* Circadian variation in O⁶-methylguanine-DNA methyltransferase activity in mouse liver, 703
- Massart C *et al.* Effect of S9788 on the efficiency of doxorubicin *in vivo* and *in vitro* in medullary thyroid carcinoma xenograft, 321
- Mastrandrea G. *See* Gebbia V, 386
- Matsuzawa A. *See* Kizu R, 248
- Mattson K. *See* Saarinen A, 890
- Maublant J. *See* Cayre A, 833
- Maugendre S. *See* Massart C, 321
- McFadden AWJ. *See* Bear HD, 299
- McGown AT. *See* Cummings J, 636
- McKeating J. *See* Werner A, 307
- McKillop D. *See* Kaisary A, 54
- Meikle I. *See* Cummings J, 636
- Meneghini G. *See* Cartei E, 48
- Merlin J-L. *See* Abderrabi M, 430; *also* Griffon-Etienne G, 660
- Mester J. *See* Raymond E, 752
- Mestroni G. *See* Bergamo A, 697
- Miklavcic D. *See* Serša G, 785
- Milas L. *See* Inoue T, 858; *also* Li C, 642
- Milross CG. *See* Inoue T, 858
- Minchinton AI *et al.* The effect of thalidomide on experimental tumors and metastases, 339
- Mitamura T. *See* Kobayashi T, 195; *also* Sakamoto S, 199
- Mitrovic LB. *See* Neškovic-Konstantinovic, 543
- Miyazaki M. *See* Kizu R, 248
- Mohammad R. *See* Maki A, 344
- Mohith A *et al.* The combination of paclitaxel with cisplatin exhibits antagonism *in vitro* against human melanoma, 493; *also* Retsas S, 161
- Moins N. *See* Cayre A, 833
- Momparler RL *et al.* Transfection of murine fibroblast cells with human cytidine deaminase cDNA confers resistance to cytosine arabinoside, 266
- Montero R. *See* del Roble Velazco M, 710
- Mora A. *See* Sartori R, 87
- Morelli S. *See* Tondelli L, 189
- Mote PA *et al.* Paclitaxel sensitizes multidrug resistant cells to radiation, 181
- Mouchard-Delmas C *et al.* Modification of the blood-brain barrier permeability by vinorelbine: effect of intracarotid infusion compared with intravenous infusion, 213
- Mountain CE. *See* Piamsomboon S, 800
- Moya SA. *See* Sartori R, 87
- Muhs MA. *See* Saunders PP, 93
- Muranishi S. *See* Hagiwara A, 780
- Nagasawa H. *See* Kobayashi T, 195
- Nagase S. *See* Watanabe S, 114; *also* Watanabe S, 866
- Naito M. *See* Watanabe T, 825
- Nakamura K *et al.* Prophylactic action of allopurinol against chemotherapy-induced stomatitis—inhibition of superoxide dismutase and proteases, 235
- Nakanishi K. *See* Une Y, 881
- Nakanishi T. *See* Kizu R, 248
- Nakayama T. *See* Sakamoto S, 199
- Nakayama Y. *See* Watanabe T, 825
- Nash A. *See* Blackledge G, 27
- Natsugoe S. *See* Nakamura K, 235
- Neškovic-Konstantinovic ZB *et al.* Daily oral etoposide in metastatic breast cancer, 543
- Nicolin A. *See* Tondelli L, 189
- Nishibe M. *See* Une Y, 881
- Nishizawa M. *See* Ishida R, 591
- Noji M. *See* Kizu R, 248
- Nooijen WJ. *See* Sparreboom A, 78
- Nord LD. *See* Martin DS, 655; *also* Stolli RL, 100
- Nusbaum NJ & Abraham T. Combination antiretroviral chemotherapy: a potential strategy in AIDS-related malignancy, 109
- Nygren N. *See* Fridborg H, 105
- O'Toole RV. *See* Malviya VK, 527
- O'Reilly S *et al.* A phase II trial of topotecan in patients with previously untreated pancreatic cancer, 410
- Ochieng J. *See* Johnson DE, 288
- Oh-Hara T. *See* Watanabe T, 825
- Ohgaki M. *See* Hagiwara A, 780; *also* Tsujimoto H, 240
- Ohkawa K. *See* Takahashi N, 687
- Ohshimo H. *See* Shirasaka T, 548
- Ohyama T. *See* Tsujimoto H, 240
- Olas B & Wachowicz B. Cisplatin-induced changes in biological activity of blood platelets: thiol-related mechanisms, 476
- Oliver L. *See* Mote PA, 181
- Ord S. *See* O'Reilly S, 410
- Orlandi L. *See* Supino R, 604
- Osaki K. *See* Tsujimoto H, 240
- Oster W. *See* Borsi JD, 121
- Ostrosky-Wegman P. *See* del Roble Velazco M, 710
- Ottaviani E. *See* Tosi P, 774
- Palfner K. *See* Bertram J, 838
- Parasuraman TV. *See* Thwaites R, 127
- Parodi S. *See* Debernardis D, 531
- Parry EM. *See* Carbonell E, 514
- Pashinsky I. *See* Iyubimov E, 60
- Paska W. *See* Thwaites R, 127
- Pastene R. *See* Sartori R, 87
- Pazdur R *et al.* Phase I trial of uracil-

- tegafur (UFT) using 5 and 28 day administration schedules: demonstration of schedule-dependent toxicities, 728
- Pécer J. *See* Chowers I, 805
- Pellacani A. *See* Tosi P, 774
- Pérez C. *See* Sartori R, 87
- Pero R. *See* Johnsson A, 483
- Peterson DC. *See* Haselsberger K, 331
- Pettit GR. *See* Maki A, 344
- Photiou A. *See* Mohith A, 493
- Piamsomboon S *et al.* Prolonged stabilisation of progressive squamous cell cancer of the cervix with interferon α and 13-*cis*-retinoic acid: report of two cases and review of the literature, 800; *also* Termrungruanglert W, 503
- Piñeyro A. *See* del Roble Velazco M, 710
- Podoloff DA. *See* Inoue T, 858
- Pourquier P. *See* Hu Y-P, 738
- Preece PE. *See* Cree IA, 630
- Psaraki K. *See* Carbonell E, 514
- Pyrhonen S. *See* Saarinen A, 890
- Radulovic SS. *See* Neškovic-Konstantinovic, 543
- Raoul M. *See* Massart C, 321
- Rapp M. *See* Martineau-Pivoteau N, 703
- Raymond E *et al.* Synergy between the non-classical thymidylate synthase inhibitor AG337[®] (Thymitaq[®]) and cisplatin in human colon and ovarian cancer cells, 752
- Raza S. *See* Maki A, 344
- Recchia E. *See* Sica G, 150
- Rencoret Gui. *See* Sartori R, 87
- Rencoret Gus. *See* Sartori R, 87
- Retas S *et al.* Taxol and vinorelbine: a new active combination for disseminated malignant melanoma, 161; *also* Mohith A, 493
- Rinaldi DA. *See* Weiss GR, 402
- Ringborg U. *See* Karlson J, 422
- Rizzi V *et al.* Liver function tests and lidocaine metabolism (MEGX test) during i.v. CMF therapy in breast cancer, 846
- Roach RW. *See* Malviya VK, 527
- Robert J. *See* Hu Y-P, 738
- Roberts JD. *See* Bear HD, 299
- Rodriguez GI. *See* Weiss GR, 402
- Rojas E. *See* del Roble Velazco M, 710
- Rolhion C. *See* Martineau-Pivoteau N, 703
- Ron IG *et al.* Advanced colorectal carcinoma: redefining the role of oral fluorouracil, 649
- Roubille N. *See* Saarinen A, 890
- Rowinsky EK. *See* O'Reilly S, 410
- Russo P. *See* Debernardis D, 531
- Saarinen A *et al.* A phase II trial of docetaxel in advanced non-small cell lung cancer, 890
- Saito T. *See* Watanabe S, 114
- Sakakura C. *See* Hagiwara A, 780; *also* Tsujimoto H, 240
- Sakamoto S *et al.* 1-(2-Tetrahydrofuryl)-5-fluorouracil in combination with uracil suppresses mammary carcinogenesis and growth of tumors induced with 7,12-dimethylbenze[*a*]anthracene in rats, 199
- Saleh M. *See* Maki A, 344
- Santoni J. *See* Lokicec E, 893
- Sariego R. *See* Sartori R, 87
- Sartori R *et al.* The novel use of Rh(I) complexes with naphthyridine ligands and poly(oxyethylene) as antitumorals, 87
- Sasaki S. *See* Tsujimoto H, 240
- Sassa S. *See* Sakamoto S, 199
- Saito T. *See* Watanabe S, 866
- Sato S. *See* Watanabe S, 114; *also* Watanabe S, 866
- Saunders PP *et al.* Metabolism and action of benzamide riboside in Chinese hamster ovary cells, 93
- Sausville EA. *See* Kaur G, 815
- Sava G. *See* Bergamo A, 697
- Sawai K. *See* Hagiwara A, 780
- Scalliet P. *See* Egelmceers A, 586
- Schipper DL & Wagener DJT. Chemotherapy of gastric cancer, 137
- Schmoll HJ. *See* Dunn TA, 795
- Scholz M. *See* Cinatl Jr. J, 766
- Seeber S. *See* Strumberg D, 415
- Sela J *et al.* A quantitative morphometric study of the kinetics of tissue regeneration after administration of cisplatin, 579
- Serša G *et al.* Electrochemotherapy with bleomycin in SA-1 tumor-bearing mice—natural resistance and immune responsiveness, 785
- Shaffer DW. *See* Weiss GR, 402
- Shah RM *et al.* *In vivo/in vitro* studies on the effects of cyclophosphamide on growth and differentiation of hamster palate, 204
- Shani J. *See* Sela J, 579
- Shapira A. *See* Lugassy G, 525
- Sharma R & Gulliya KS. *In situ* stimulation of topoisomerase II-induced cleavage sites in the *c-myc* protooncogene by antitumor agent pMC540 is associated with gene expression, 293
- Shimamoto Y. *See* Shirasaka T, 548
- Shimamura T. *See* Une Y, 881
- Shimosatao K. *See* Watanabe S, 866
- Shinkawa T. *See* Nakamura K, 235
- Shirasaka T *et al.* Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators, 548
- Shoshan MC. *See* Karlson J, 422
- Sica G *et al.* Interferon and hormone sensitivity of endocrine-related tumors, 150
- Siganos CS. *See* Chowers I, 805
- Silvestrini R. *See* Supino R, 604
- Singh SS *et al.* Drug retention following intravesical delivery of fluorouracil therapeutic adhesive in C3H mouse bladder, 507
- Smith KM. *See* Singh SS, 507
- Smyth JE. *See* Cummings J, 636
- Solomon A. *See* Chowers I, 805
- Sordo M. *See* del Roble Velazco M, 710
- Sparreboom A *et al.* Tissue distribution, metabolism and excretion of paclitaxel in mice, 78
- Stefanou G. *See* Carbonell E, 514
- Steger M. *See* Kudelka AP, 398
- Stein WD. *See* Ayesh S, 678; *also* Lyubimov E, 60
- Stolfi RL *et al.* Enhanced antitumor activity of an adriamycin +5-fluorouracil combination when preceded by biochemical modulation, 100; *also* Martin DS, 655
- Strumberg D *et al.* Bendamustine hydrochloride activity against doxorubicin-resistant human breast carcinoma cell lines, 415
- Stuart OA. *See* Jacquet P, 596
- Subedi AMC. *See* Cree IA, 630
- Sugarbaker PH. *See* Jacquet P, 596
- Supino R *et al.* Modulation of melphalan cytotoxic activity in human melanoma cell lines, 604
- Surve-Iyer R. *See* Saunders PP, 93
- Sutherland LA. *See* Cree IA, 630
- Suzuki S. *See* Sakamoto S, 199
- Sypek JP. *See* Izquierdo MA, 275
- Tabaro G. *See* Cartei F, 48; *also* Rizzi V, 846
- Tabata Y. *See* Hagiwara A, 780
- Takahashi N *et al.* Pharmacokinetic analysis of protein-conjugated doxorubicin (DXR) and its degraded adducts in DXR-sensitive and -resistant rat hepatoma cells, 687
- Takahashi T. *See* Hagiwara A, 780; *also* Tsujimoto H, 240
- Takeda Y. *See* Kizu R, 248
- Talavera A. *See* Avilés A, 392
- Tamminen K. *See* Saarinen A, 890
- Tamoda A. *See* Ishida R, 591
- Tansey W. *See* Inoue T, 858
- Tashiro T. *See* Kizu R, 248
- Termrungruanglert W *et al.* Remission of refractory gestational trophoblastic disease with high-dose paclitaxel,

- 503; *also* Kudelka AP, 885; *also* Piamsomboon S, 800
- Testa A. *See* Gebbia V, 386; *also* Gebbia V, 734
- Thatcher N. *See* Martin C, 351
- Thomas DGT. *See* Haselsberger K, 331
- Thwaites R *et al.* Re: Cost-effectiveness of 5-hydroxytryptamine₃ receptor agonists: a retrospective comparison of ondansetron and granisetron, 127
- Tiberghien F & Looor E. Ranking of P-glycoprotein substrates and inhibitors by a calcein-AM fluorometry screening assay, 568; *also* Didier A, 257
- Timmermann BN. *See* Valcic S, 461
- Tondelli L *et al.* Terminally L-modified oligonucleotides: pairing, stability and biological properties, 189
- Toriizuka K. *See* Kobayashi T, 195
- Tornos C. *See* Kudelka AP, 885
- Tosi P *et al.* Retinoids increase idarubicin cytotoxicity in human myeloid leukemia cell lines, 774
- Tsujimoto H *et al.* Cisplatin microcrystals suspended in oil: pathological study of acute toxicity in mice, 240; *also* Hagiwara A, 780
- Tsuruo T. *See* Watanabe T, 825
- Tubiana-Hulin M. *See* Lokicec E, 893
- Tura S. *See* Tosi P, 774
- Turner AJ. *See* Bear HD, 299
- Uchino J. *See* Une Y, 881
- Une Y *et al.* A pharmacological pilot study: application of an intermittent schedule of oral uracil and fluorouracil (UFT) for hepatocellular carcinoma patients, 881
- Unelius R. *See* Karlson J, 422
- Untch M. *See* Cree IA, 630
- Vadhan-Raj S. *See* Kudelka AP, 885
- Vaglini M. *See* Supino R, 604
- Valcic S *et al.* Inhibitory effect of six green tea catechins and caffeine on the growth of four selected human tumor cell lines, 461
- Van Hoff DD. *See* Weiss GR, 402
- Van Oosterom AI. *See* Dirix LY, 175; *also* Egelmeers A, 586
- van Tellingen O. *See* Sparreboom A, 78
- Varma DG. *See* Kudelka AP, 885
- Vecht CJ. *See* Dellemijn PLI, 3
- Vermeulen PB. *See* Dirix LY, 175
- Verrelle P. *See* Cayre A, 833
- Verschraegen CE. *See* Kudelka AP, 398; *also* Kudelka AP, 885; *also* Piamsomboon S, 800; *also* Termrungruangler W, 503
- Vigevani E. *See* Cartei E, 48
- Visani G. *See* Tosi P, 774
- Vistelle R. *See* Mouchard-Delmas C, 213
- Voest EE. Inhibitors of angiogenesis in a clinical perspective, 723
- Vogel J-C. *See* Cinatl Jr J, 766
- Von Hoff DD. *See* Izquierdo MA, 275
- Vrignaud P. *See* Bissery MC, 437
- Wachowicz B. *See* Ols B, 476
- Wächter GA. *See* Valcic S, 461
- Wagener DJT. *See* Schipper DL, 137
- Wallace S. *See* Inoue T, 858; *also* Kuang L, 220; *also* Li C, 642
- Wang C-H. *See* Liao C-T, 228
- Wasi S. *See* Clements MK, 851
- Watanabe S *et al.* Therapeutic significance of the polyamine level in tissues of rats treated with adriamycin and cisplatin, 114; *also* Polyamine levels in various tissues of rats treated with 3-hydroxy-4-methoxycinnamic acid and 3,4-dimethoxycinnamic acid, 866
- Watanabe T *et al.* Cremophor EL reversed multidrug resistance *in vitro* but not in tumour-bearing mouse models, 825
- Weill S. *See* Lokicec E, 893
- Weiss GR *et al.* A randomized phase I study of oral etoposide with or without granulocyte-macrophage colony-stimulating factor for the treatment of patients with advanced cancer, 402
- Wendt KR. *See* Minchinton AI, 339
- Wenger R. *See* Didier A, 257
- Wennerberg J. *See* Johnsson A, 483
- Werner A *et al.* Inhibition of experimental liver metastasis by combined treatment with tamoxifen and interferon, 307
- Wiczewski M. *See* Mouchard-Delmas C, 213
- Wilking N. *See* Karlson J, 422
- Wilmanns W. *See* Gerl A, 716
- Wright KC. *See* Kuang L, 220
- Wymer J. *See* Valcic S, 461
- Yalowich JC. *See* Hasinoff BB, 558
- Yamada K. *See* Nakamura K, 235
- Yamaguchi M. *See* Shirasaka T, 548
- Yamamoto A. *See* Hagiwara A, 780
- Yamanaka S. *See* Ishida R, 591
- Yamazaki J. *See* Hagiwara A, 780; *also* Tsujimoto H, 240
- Yang DJ. *See* Inoue T, 858; *also* Kuang L, 220; *also* Li C, 642
- Yang T-S. *See* Liao C-T, 228
- Yonekura K. *See* Shirasaka T, 548
- Yoshimura S. *See* Sakamoto S, 199
- Yoshinaka H. *See* Nakamura K, 235
- Young AV. *See* Shah RM, 204
- Yu D. *See* Li C, 642
- Zaffaroni N. *See* Supino R, 604
- Zunino E. *See* Supino R, 604